Table 3 Clinical trials using LPA signaling as a therapeutic target for different pathologiesa
From: Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies
Study | ClinicalTrials.gov Identifier | Sponsor | Disease | Phase | Drug inhibitor |
|---|---|---|---|---|---|
Safety and efficacy of a LPA receptor antagonist in idiopathic pulmonary fibrosis | NCT01766817 | Bristol-Myers Squibb | Idiopathic pulmonary fibrosis | 2 | LPAR1 inhibitor drug: BMS-986020 |
Safety, tolerability, pharmacokinetics, and pharmacodynamics of BBT-877 in healthy subjects | NCT03830125 | Bridge Biotherapeutics, Inc. | Idiopathic pulmonary fibrosis | 1 | ATX inhibitor |
Phase 2a, open-label study of two doses of GLPG1837 in subjects with cystic fibrosis and the S1251N mutation | NCT02690519 | Galapagos NV | Cystic fibrosis | 2 | ATX inhibitor |
Phase 2a, open-label study of multiple doses of GLPG1837 in subjects with cystic fibrosis and the G551D mutation | NCT02707562 | Galapagos NV | Cystic fibrosis | 2 | ATX inhibitor |
Evaluation of the pharmacokinetics, safety and tolerability of a single dose of GLPG3067 administered as solid formulation in male subjects with cystic fibrosis | NCT03589313 | Galapagos NV | Cystic fibrosis | 1 | ATX inhibitor |
Evaluation of the pharmacokinetics, safety and tolerability of a single dose of GLPG2737 administered as oral suspension in male subjects with cystic fibrosis | NCT03450720 | Galapagos NV | Cystic fibrosis | 1 | ATX inhibitor |
Phase 2a, randomized, double-blinded placebo-controlled study to evaluate GLPG2737 in orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation | NCT03474042 | Galapagos NV | Cystic fibrosis | 2 | ATX inhibitor |
Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with cystic fibrosis harboring one F508del CFTR mutation and a second gating (Class III) mutation | NCT03045523 | Galapagos NV | Cystic fibrosis | 2 | ATX inhibitor |
Assessment of safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of the combination of GLPG2451 and GLPG2222, with or without GLPG2737, in adult subjects with cystic fibrosis | NCT03540524 | Galapagos NV | Cystic fibrosis | 1 | ATX inhibitor |
Phase 2a, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with cystic fibrosis who are homozygous for the F508del mutation | NCT03119649 | Galapagos NV | Cystic fibrosis | 2 | ATX inhibitor |
Phase 2 randomized, double-blinded, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis | NCT03725852 | Galapagos NV | Idiopathic pulmonary fibrosis | 2 | ATX inhibitor |
Phase 3, randomized, double-blinded, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis | NCT03733444 | Galapagos NV | Idiopathic pulmonary fibrosis | 3 | ATX inhibitor |
Phase 3, randomized, double-blinded, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis | NCT03711162 | Galapagos NV | Idiopathic pulmonary fibrosis | 3 | ATX inhibitor |
Randomized, double-blind, parallel group, placebo-controlled, multicenter, exploratory phase 2a study to assess safety, tolerability, pharmacokinetic and pharmacodynamic properties of GLPG1690 administered for 12 weeks in subjects with idiopathic pulmonary fibrosis (IPF) | NCT02738801 | Galapagos NV | Idiopathic pulmonary fibrosis | 2 | ATX inhibitor |
Double-blinded, randomized, 8-week placebo-controlled, and 16-week open-label extension study investigating the safety, pharmacokinetics and pharmacodynamics of SAR100842 given orally to patients with diffuse cutaneous systemic sclerosis | NCT01651143 | Sanofi | Systemic sclerosis | 2 | LPAR1 inhibitor SAR100842 |
